Immunocore Holdings plc

NasdaqGS:IMCR Stock Report

Market Cap: US$1.5b

Immunocore Holdings Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Bahija Jallal

Chief executive officer

US$11.7m

Total compensation

CEO salary percentage6.3%
CEO tenure6yrs
CEO ownershipn/a
Management average tenure2yrs
Board average tenure4.8yrs

Recent management updates

Recent updates

There Is A Reason Immunocore Holdings plc's (NASDAQ:IMCR) Price Is Undemanding

Jan 08
There Is A Reason Immunocore Holdings plc's (NASDAQ:IMCR) Price Is Undemanding

Immunocore Is Adequately Valued, But Its Prospects Are Uncertain

Dec 10

Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?

Oct 24
Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?

Immunocore Holdings plc's (NASDAQ:IMCR) Business And Shares Still Trailing The Industry

Sep 19
Immunocore Holdings plc's (NASDAQ:IMCR) Business And Shares Still Trailing The Industry

Immunocore Holdings: KIMMTRAK Success, Diverse Pipeline, And Potential Big Pharma Appeal

Aug 12

Is Immunocore Holdings plc (NASDAQ:IMCR) Trading At A 33% Discount?

Jul 24
Is Immunocore Holdings plc (NASDAQ:IMCR) Trading At A 33% Discount?

Immunocore Holdings plc's (NASDAQ:IMCR) 28% Dip In Price Shows Sentiment Is Matching Revenues

Jun 16
Immunocore Holdings plc's (NASDAQ:IMCR) 28% Dip In Price Shows Sentiment Is Matching Revenues

Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?

May 11
Is Immunocore Holdings (NASDAQ:IMCR) Using Debt Sensibly?

Immunocore Holdings plc (NASDAQ:IMCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

May 11
Immunocore Holdings plc (NASDAQ:IMCR) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Are Investors Undervaluing Immunocore Holdings plc (NASDAQ:IMCR) By 25%?

Apr 05
Are Investors Undervaluing Immunocore Holdings plc (NASDAQ:IMCR) By 25%?

Here's Why Immunocore Holdings (NASDAQ:IMCR) Can Manage Its Debt Despite Losing Money

Jan 22
Here's Why Immunocore Holdings (NASDAQ:IMCR) Can Manage Its Debt Despite Losing Money

Immunocore Holdings: Vulnerable To Profit Taking After Big Rally

Jan 21

Revenues Not Telling The Story For Immunocore Holdings plc (NASDAQ:IMCR) After Shares Rise 37%

Dec 18
Revenues Not Telling The Story For Immunocore Holdings plc (NASDAQ:IMCR) After Shares Rise 37%

Some Confidence Is Lacking In Immunocore Holdings plc's (NASDAQ:IMCR) P/S

May 08
Some Confidence Is Lacking In Immunocore Holdings plc's (NASDAQ:IMCR) P/S

Forecast: Analysts Think Immunocore Holdings plc's (NASDAQ:IMCR) Business Prospects Have Improved Drastically

Nov 16
Forecast: Analysts Think Immunocore Holdings plc's (NASDAQ:IMCR) Business Prospects Have Improved Drastically

Immunocore: Attractive Commercial-Stage Biopharma

Oct 05

Need To Know: Analysts Are Much More Bullish On Immunocore Holdings plc (NASDAQ:IMCR)

Aug 12
Need To Know: Analysts Are Much More Bullish On Immunocore Holdings plc (NASDAQ:IMCR)

Immunocore GAAP EPS of -$0.17, revenue of $38.92M

Aug 10

Immunocore to raise $140M in private placement financing

Jul 18

CEO Compensation Analysis

How has Bahija Jallal's remuneration changed compared to Immunocore Holdings's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$47m

Jun 30 2024n/an/a

-US$55m

Mar 31 2024n/an/a

-US$60m

Dec 31 2023US$12mUS$735k

-US$55m

Sep 30 2023n/an/a

-US$69m

Jun 30 2023n/an/a

-US$61m

Mar 31 2023n/an/a

-US$52m

Dec 31 2022US$1mUS$700k

-US$53m

Sep 30 2022n/an/a

-US$62m

Jun 30 2022n/an/a

-US$112m

Mar 31 2022n/an/a

-US$156m

Dec 31 2021US$35mUS$700k

-US$180m

Sep 30 2021n/an/a

-US$150m

Jun 30 2021n/an/a

-US$139m

Mar 31 2021n/an/a

-US$116m

Dec 31 2020US$1mn/a

-US$101m

Compensation vs Market: Bahija's total compensation ($USD11.68M) is above average for companies of similar size in the US market ($USD5.47M).

Compensation vs Earnings: Bahija's compensation has increased whilst the company is unprofitable.

CEO

Bahija Jallal (63 yo)

6yrs

Tenure

US$11,678,834

Compensation

Dr. Bahija Jallal, Ph.D. serves as Director of Outpace Bio, Inc. from March 2023. She serves as Chief Executive Officer and Director of Immunocore Holdings plc (formerly known as Immunocore Holdings Limite...

Leadership Team

NamePositionTenureCompensationOwnership
Bahija Jallal
CEO & Executive Director6yrsUS$11.68mno data
Travis Coy
CFO, Executive VP & Head of Corporate Developmentno datano datano data
Tina Leger
Chief Human Resources Officer2.9yrsUS$1.04mno data
David Berman
Executive Vice President of Research & Development6yrsUS$4.40m0%
$ 0
John Trainer
SVP & Chief Operating Officerless than a yearno datano data
John Goll
SVP, Finance & Chief Accounting Officerless than a yearno datano data
Annelise Vuidepot
Senior VPno datano datano data
Sean Buckley
VP & Chief Information Officerless than a yearno datano data
Clayton Robertson
Head of Investor Relationsno datano datano data
Lily Hepworth
Senior VP4yrsno datano data
Elizabeth Jobes
Chief Compliance Officerless than a yearno datano data
Sébastien Desprez
Vice President of Communications3yrsno datano data

2.0yrs

Average Tenure

51.5yo

Average Age

Experienced Management: IMCR's management team is not considered experienced ( 2 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Bahija Jallal
CEO & Executive Director6yrsUS$11.68mno data
John Bell
Independent Non-Executive Chairman9.8yrsUS$416.99k0.027%
$ 406.7k
Kristine Peterson
Independent Non-Executive Director7.2yrsUS$389.49k0%
$ 0
Robert Perez
Independent Non-Executive Director5.3yrsno datano data
Roy Steven Herbst
Independent Non-Executive Director4yrsUS$386.99k0%
$ 0
Peter Ratcliffe
Independent Non-Executive Director4.2yrsUS$384.49k0.00067%
$ 10.1k
Ranjeev Krishana
Directorless than a yearno datano data
Siddharth Kaul
Independent Non-Executive Director2.6yrsUS$386.99k0%
$ 0

4.8yrs

Average Tenure

63.5yo

Average Age

Experienced Board: IMCR's board of directors are considered experienced (4.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 20:35
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Immunocore Holdings plc is covered by 22 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Peter LawsonBarclays
Olga SmolentsevaBryan Garnier & Co